Benefits and Safety of Tirofiban among Older Patients With Non-ST-elevation Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention
Peng-cheng HE
Ning TAN
Ji-yan CHEN
Ying-ling ZHOU
Jian-fang LUO
Zhu-jun CHEN
摘要：Background Glycoprotein(GP)Ⅱb/Ⅲa antagonist has been shown its efficacy and safety in high-risk patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI). Whether GPⅡb/Ⅲa antagonist is as effective and safe in older patients (≥ 65 years old) as in younger patients remains unclear.Objectives Our objective was to determine whether GPⅡb/Ⅲa antagonist tirofiban was effective and safe in patients aged≥65 years who underwent PCI. Methods From September 2006 to August 2008, 622 patients with non-ST-elevation ACS (NSTE ACS) were randomized to receive either tirofiban (n=313) or placebo (n=309). The infusion duration was 48 hours for both groups. Incidence of major adverse cardiac events (MACE) was assessed at 180 days.Incidence of bleeding was monitored through 24 hours after trial therapy was discontinued. Results The incidence of MACE for the tirofiban group versus the placebo group was 7.3% vs 12.6% (P＜0.05). Among these MACE, death rate was 2.6% vs 4.6% (P=0.198), non-fatal MI was 3.8% vs 6.5% (P=0.150), and target vessel revascularization was 1.3% vs 1.6% (P=0.751), in the two groups, respectively. The total bleeding rate for the tirofiban group versus the placebo group was 28.1% vs 6.8% (P＜0.05). The TIMI major and minor bleeding rates for the tirifiban versus the placebo group were 2.2% vs 1.6% (P＞0.05) and 25.9% vs 5.2% (P＜0.05), respectively. Conclusions Tirofiban appears to be effective and safe in older patients with ACS who underwent PCI.
机标关键词：
分类号：R5(内科学)
论文发表日期：2009-07-02
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：6( 120-125 )
英文信息